Home > Publications database > Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. > print |
001 | 126257 | ||
005 | 20240228140818.0 | ||
024 | 7 | _ | |a 10.1016/j.stemcr.2015.03.005 |2 doi |
024 | 7 | _ | |a pmid:25921812 |2 pmid |
024 | 7 | _ | |a pmc:PMC4437464 |2 pmc |
024 | 7 | _ | |a altmetric:3973369 |2 altmetric |
037 | _ | _ | |a DKFZ-2017-02372 |
041 | _ | _ | |a eng |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Cheng, Peng |b 0 |
245 | _ | _ | |a Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. |
260 | _ | _ | |a Maryland Heights, MO |c 2015 |b Cell Press |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1508404286_7026 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a Glioblastoma is a highly lethal cancer for which novel therapeutics are urgently needed. Two distinct subtypes of glioblastoma stem-like cells (GSCs) were recently identified: mesenchymal (MES) and proneural (PN). To identify mechanisms to target the more aggressive MES GSCs, we combined transcriptomic expression analysis and kinome-wide short hairpin RNA screening of MES and PN GSCs. In comparison to PN GSCs, we found significant upregulation and phosphorylation of the receptor tyrosine kinase AXL in MES GSCs. Knockdown of AXL significantly decreased MES GSC self-renewal capacity in vitro and inhibited the growth of glioblastoma patient-derived xenografts. Moreover, inhibition of AXL with shRNA or pharmacologic inhibitors also increased cell death significantly more in MES GSCs. Clinically, AXL expression was elevated in the MES GBM subtype and significantly correlated with poor prognosis in multiple cancers. In conclusion, we identified AXL as a potential molecular target for novel approaches to treat glioblastoma and other solid cancers. |
536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
650 | _ | 7 | |a Antigens, CD44 |2 NLM Chemicals |
650 | _ | 7 | |a Proto-Oncogene Proteins |2 NLM Chemicals |
650 | _ | 7 | |a RNA, Small Interfering |2 NLM Chemicals |
650 | _ | 7 | |a Receptor Protein-Tyrosine Kinases |0 EC 2.7.10.1 |2 NLM Chemicals |
650 | _ | 7 | |a axl receptor tyrosine kinase |0 EC 2.7.10.1 |2 NLM Chemicals |
700 | 1 | _ | |a Phillips, Emma |0 P:(DE-He78)830be4979a39935ac6272eaebad5982a |b 1 |u dkfz |
700 | 1 | _ | |a Kim, Sung-Hak |b 2 |
700 | 1 | _ | |a Taylor, David |b 3 |
700 | 1 | _ | |a Hielscher, Thomas |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 4 |u dkfz |
700 | 1 | _ | |a Puccio, Laura |0 P:(DE-He78)39a8becd6fa9602e4871d18f3f6f8e09 |b 5 |u dkfz |
700 | 1 | _ | |a Hjelmeland, Anita B |b 6 |
700 | 1 | _ | |a Lichter, Peter |0 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c |b 7 |u dkfz |
700 | 1 | _ | |a Nakano, Ichiro |b 8 |
700 | 1 | _ | |a Goidts, Violaine |0 P:(DE-HGF)0 |b 9 |e Last author |
773 | _ | _ | |a 10.1016/j.stemcr.2015.03.005 |g Vol. 4, no. 5, p. 899 - 913 |0 PERI:(DE-600)2720528-9 |n 5 |p 899 - 913 |t Stem cell reports |v 4 |y 2015 |x 2213-6711 |
909 | C | O | |o oai:inrepo02.dkfz.de:126257 |p VDB |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)830be4979a39935ac6272eaebad5982a |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)39a8becd6fa9602e4871d18f3f6f8e09 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-HGF)0 |
913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |2 G:(DE-HGF)POF3-300 |v Functional and structural genomics |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
914 | 1 | _ | |y 2015 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b STEM CELL REP : 2015 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC (No Version) |0 LIC:(DE-HGF)CCBYNCNV |2 V:(DE-HGF) |b DOAJ |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b STEM CELL REP : 2015 |
920 | 1 | _ | |0 I:(DE-He78)B060-20160331 |k B060 |l Molekulare Genetik |x 0 |
920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 1 |
920 | 1 | _ | |0 I:(DE-He78)B067-20160331 |k B067 |l Translationale Zielmoleküle für Hirntumoren |x 2 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)B060-20160331 |
980 | _ | _ | |a I:(DE-He78)C060-20160331 |
980 | _ | _ | |a I:(DE-He78)B067-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|